SAN FRANCISCO and SUZHOU, China, Oct. 28, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces the latest clinical results of a multicenter, open-label Phase 2 study (ClinicalTrials.gov, NCT05970978) of picankibart (R&D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, in patients with plaque psoriasis previously responded inadequately to other biologics. Robust efficacy and favorable safety profile were observed.
Biologics have become the mainstream systemic treatment for psoriasis; however, a considerable proportion of patients do not respond to initial biologic agents. This is the first clinical study in China evaluating a switch from other biologics to an IL-23p19-targeted drug. The study demonstrated that after 16-week of treatment with picankibart, the majority of patients (64.6%,42/65) who had inadequate response to previous biologic agents (mainly those targeting IL-17), achieved skin clearance or near clearance with a sPGA of 0 or 1. Results from this study will provide evidence for novel long-term treatment regimens for patients with moderate to severe psoriasis. Innovent biologics will advance the Phase 3 clinical trial of picankibart.
The first clinical trial in China for switching from other biologics to an IL-23p19 antibody in the field of psoriasis
This study aims to evaluate the efficacy and safety in patients with plaque psoriasis who switched from other biologics to picankibart. A total of 152 patients, previously treated with marketed biologics for plaque psoriasis—including IL-17 inhibitors and TNF-α inhibitors—were enrolled. Patients with prior inadequate response at baseline (defined as a static Physician’s Global Assessment [sPGA] score of ≥2, or body surface area [BSA] of ≥3%) received 200 mg of subcutaneously picankibart at weeks 0, 4, and 8 followed by dosing at every 12 weeks until week 32 and follow-up until week 44. Responders at baseline (sPGA score of 0 or 1 and BSA of